Pamidronate Disodium Injection for Hypercalcemia/Tumour
Model No.: pam-1
Pamidronate disodium injection for hypercalcemia/tumour
Pamidronic acid (INN) or pamidronate disodium (USAN), pamidronate disodium pentahydrate is a nitrogen-containing bisphosphonate, used to prevent osteoporosis. It is marketed by Novartis under the brand name Aredia. In India, it is marketed by Curacell Biotech under the brand name Pamimed.
It is used to prevent bone loss, and treat osteoporosis. It is also used to strengthen bone in Paget's disease, to prevent bone loss due to steroid use, and in certain cancers with high propensity to bone, such as multiple myeloma. In multiple myeloma, it is usually administered as an intravenous infusion, lasting about 3 hours. The therapy is repeated monthly, and lasts for the life of the patient. Due to its ability to sequester calcium in bone, it is also used to treat high calcium levels. It is also used as an experimental treatment of the bone disorder known as Osteogenesis Imperfecta. It has been studied in the treatment of Complex Regional Pain Syndrome.
Intravenous, usually 90 mg monthly. 30 mg, 60 mg, 90 mg and for hospitals, 120 mg vials are available, mixed with mannitol.
Common side effects include bone pain, low calcium levels, nausea, and dizziness. Osteonecrosis of the jaw is a rare complication which has been associated with the use of bisphosphonates, including pamidronate.
Pamidronate activates human γδ T cells in vitro and in vivo, which may lead to flu-like symptoms upon administration.
Contact us if you need more details on Pamidronate Disodium. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Hypercalcemia、Tumour. If these products fail to match your need, please contact us and we would like to provide relevant information.
Product Categories : Anti-Cancer Drug
Premium Related Products